Akouos Inc - AKUS
Akouos Inc. (NASDAQ: AKUS) is a biotechnology company focused on developing gene therapies for individuals with disabling hearing loss. The company's lead product candidate, AK-OTOF, is designed to restore hearing function in individuals with sensorineural hearing loss caused by a mutation in the OTOF gene. Akouos is also developing gene therapies for other forms of hearing loss, including age-related and noise-induced hearing loss. The company was founded in 2016 and is headquartered in Boston, Massachusetts. Akouos went public in 2021 and is traded on the Nasdaq stock exchange.
|
|
|
|
NVST
STRL
JHMB
CORN
TTNP
GDXU
FENG
RTK
DBAW
ICE
DJIA
TITN
|
Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy |
Refund Policy | Disclaimer